Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.

Jun S, Clapp B, Zlotkowska D, Hoyt T, Holderness K, Maddaloni M, Pascual DW.

Int Immunol. 2012 Feb;24(2):117-28. doi: 10.1093/intimm/dxr106. Epub 2011 Dec 29.

2.

Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A.

Maddaloni M, Staats HF, Mierzejewska D, Hoyt T, Robinson A, Callis G, Kozaki S, Kiyono H, McGhee JR, Fujihashi K, Pascual DW.

J Immunol. 2006 Oct 15;177(8):5524-32.

3.

Adenovirus F protein as a delivery vehicle for botulinum B.

Clapp B, Golden S, Maddaloni M, Staats HF, Pascual DW.

BMC Immunol. 2010 Jul 7;11:36. doi: 10.1186/1471-2172-11-36.

4.

Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.

Staats HF, Fielhauer JR, Thompson AL, Tripp AA, Sobel AE, Maddaloni M, Abraham SN, Pascual DW.

PLoS One. 2011 Jan 27;6(1):e16532. doi: 10.1371/journal.pone.0016532.

5.

Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.

Mustafa W, Al-Saleem FH, Nasser Z, Olson RM, Mattis JA, Simpson LL, Schnell MJ.

Vaccine. 2011 Jun 20;29(28):4638-45. doi: 10.1016/j.vaccine.2011.04.045. Epub 2011 May 5.

7.

Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.

Yamada T, Kataoka S, Ogasawara K, Ishimitsu R, Hashigucci K, Suzuki T, Kawauchi H.

Rhinology. 2005 Sep;43(3):190-8.

PMID:
16218512
8.

Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, Wilson BA, Fritz RB, Johnson EA, Barbieri JT.

Infect Immun. 2005 Oct;73(10):6998-7005.

9.

Enhancing the protective immune response against botulism.

Przedpelski A, Tepp WH, Kroken AR, Fu Z, Kim JJ, Johnson EA, Barbieri JT.

Infect Immun. 2013 Jul;81(7):2638-44. doi: 10.1128/IAI.00382-13. Epub 2013 May 13.

10.
11.

Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Henkel JS, Tepp WH, Przedpelski A, Fritz RB, Johnson EA, Barbieri JT.

Vaccine. 2011 Oct 13;29(44):7688-95. doi: 10.1016/j.vaccine.2011.07.134. Epub 2011 Aug 10.

12.

Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.

Mukamoto M, Maeda H, Kohda T, Nozaki C, Takahashi M, Kozaki S.

Jpn J Infect Dis. 2013;66(1):46-50.

13.

Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.

Moreira C Jr, da Cunha CE, Moreira GM, Mendonça M, Salvarani FM, Moreira ÂN, Conceição FR.

Anaerobe. 2016 Aug;40:58-62. doi: 10.1016/j.anaerobe.2016.05.012. Epub 2016 May 25.

PMID:
27236078
14.

Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.

Ruwona TB, Xu H, Li J, Diaz-Arévalo D, Kumar A, Zeng M, Cui Z.

Hum Vaccin Immunother. 2016 May 3;12(5):1188-92. doi: 10.1080/21645515.2015.1122147. Epub 2016 Feb 2.

15.

An adenoviral vector-based mucosal vaccine is effective in protection against botulism.

Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M.

Gene Ther. 2009 Mar;16(3):367-75. doi: 10.1038/gt.2008.181. Epub 2009 Jan 8.

PMID:
19129860
16.

Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.

Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, Frenzel A, Schirrmann T, Thullier P, Sesardic D, Hust M.

MAbs. 2014 Mar-Apr;6(2):446-59. doi: 10.4161/mabs.27773. Epub 2014 Jan 9.

17.

Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice.

Huang CF, Wu TC, Chu YH, Hwang KS, Wang CC, Peng HJ.

Scand J Immunol. 2008 Nov;68(5):502-10. doi: 10.1111/j.1365-3083.2008.02172.x. Epub 2008 Sep 12.

18.

Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice.

Amuguni JH, Lee S, Kerstein KO, Brown DW, Belitsky BR, Herrmann JE, Keusch GT, Sonenshein AL, Tzipori S.

Vaccine. 2011 Jun 24;29(29-30):4778-84. doi: 10.1016/j.vaccine.2011.04.083. Epub 2011 May 10.

PMID:
21565244
19.

Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.

Cuburu N, Kweon MN, Hervouet C, Cha HR, Pang YY, Holmgren J, Stadler K, Schiller JT, Anjuère F, Czerkinsky C.

J Immunol. 2009 Dec 15;183(12):7851-9. doi: 10.4049/jimmunol.0803740.

20.

A novel neurotoxoid vaccine prevents mucosal botulism.

Kobayashi R, Kohda T, Kataoka K, Ihara H, Kozaki S, Pascual DW, Staats HF, Kiyono H, McGhee JR, Fujihashi K.

J Immunol. 2005 Feb 15;174(4):2190-5.

Supplemental Content

Support Center